Tracking survival in advanced liver cancer patients on new immune drugs
NCT ID NCT07321067
Summary
This study aims to track how well patients with advanced liver cancer do while receiving immune checkpoint inhibitor drugs as part of their regular treatment. Researchers will follow 75 patients to measure how long they live and how long the cancer stays controlled, while also monitoring treatment side effects. The goal is to better understand which patients benefit most from these therapies to guide future care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sohag university hospitals
Sohag, Sohag Governorate, 82511, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
sSohag oncology centre
Sohag, Sohag Governorate, 82511, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.